Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD–scid IL-2rgnull RIP-DTR mice engrafted with human islets
Open Access
- 1 August 2015
- journal article
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 8, 387-398
Abstract
Objective: Glucagon-like peptide-1 induces glucose-dependent insulin secretion and, in rodents, increases proliferation and survival of pancreatic beta cells. To investigate the effects on human beta cells, we used immunodeficient mice transplanted with human islets. The goal was to determine whether lixisenatide, a glucagon-like peptide-1 receptor agonist, improves human islet function and survival in vivo. Methods: Five independent transplant studies were conducted with human islets from five individual donors. Diabetic human islet-engrafted immunodeficient mice were treated with lixisenatide (50, 150, and 500 µg/kg) or vehicle. Islet function was determined by blood glucose, plasma human insulin/C-peptide, and glucose tolerance tests. Grafts were analyzed for total beta- and alpha-cell number, percent proliferation, and levels of apoptosis. Results: Diabetic mice transplanted with marginal human islet mass and treated with lixisenatide were restored to euglycemia more rapidly than vehicle-treated mice. Glucose tolerance tests, human plasma insulin, and glucose-stimulation indices of lixisenatide-treated mice were significantly improved compared to vehicle-treated mice. The percentages of proliferating or apoptotic beta cells at graft recovery were not different between lixisenatide-treated and vehicle-treated mice. Nevertheless, in one experiment we found a significant twofold to threefold increase in human beta-cell numbers in lixisenatide-treated compared to vehicle-treated mice. Conclusion: Diabetic human islet-engrafted immunodeficient mice treated with lixisenatide show improved restoration of normoglycemia, human plasma insulin, and glucose tolerance compared to vehicle-treated mice engrafted with the same donor islets. Because the proliferative capacity of human beta cells is limited, improved beta-cell survival coupled with enhanced beta-cell function following lixisenatide treatment may provide the greatest benefit for diabetic patients with reduced functional islet mass.Keywords
This publication has 39 references indexed in Scilit:
- Pronounced reduction of postprandial glucagon by lixisenatide: a meta‐analysis of randomized clinical trialsDiabetes, Obesity and Metabolism, 2014
- Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγnull mice treated with alogliptinDiabetes, Metabolic Syndrome and Obesity, 2013
- Lixisenatide: First Global ApprovalDrugs, 2013
- Hyperglycemia-Induced Proliferation of Adult Human Beta Cells Engrafted Into Spontaneously Diabetic Immunodeficient NOD-Rag1null IL2rγnull Ins2Akita MicePancreas, 2011
- Significant Human β-Cell Turnover Is Limited to the First Three Decades of Life as Determined byin VivoThymidine Analog Incorporation and Radiocarbon DatingThe Journal of Clinical Endocrinology & Metabolism, 2010
- Exendin-4 Potentiates Insulinotropic Action Partly via Increasing β-Cell Proliferation and Neogenesis and Decreasing Apoptosis in Association With the Attenuation of Endoplasmic Reticulum Stress in Islets of Diabetic RatsJournal of Pharmacological Sciences, 2009
- Enhanced Protection against Cytokine- and Fatty Acid-induced Apoptosis in Pancreatic Beta Cells by Combined Treatment with Glucagon-like Peptide-1 Receptor Agonists and Insulin AnaloguesHormone and Metabolic Research, 2008
- Assessment of Human Pancreatic Islet Architecture and Composition by Laser Scanning Confocal MicroscopyJournal of Histochemistry & Cytochemistry, 2005
- Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human IsletsEndocrinology, 2003
- GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cellsDiabetes/Metabolism Research and Reviews, 2003